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Abstract
The vascular network is established and maintained through the processes of vasculogenesis and angiogenesis, which are 
tightly regulated during embryonic and postnatal life. The formation of a functional vasculature requires critical cellular 
mechanisms, such as cell migration, proliferation and adhesion, which are dependent on the activity of small Rho GTPases, 
controlled in part by the dedicator of cytokinesis (DOCK) protein family. Whilst the majority of DOCK proteins are associ-
ated with neuronal development, a growing body of evidence has indicated that members of the DOCK family may have key 
functions in the control of vasculogenic and angiogenic processes. This is supported by the involvement of several angiogenic 
signalling pathways, including chemokine receptor type 4 (CXCR4), vascular endothelial growth factor (VEGF) and phos-
phatidylinositol 3-kinase (PI3K), in the regulation of specific DOCK proteins. This review summarises recent progress in 
understanding the respective roles of DOCK family proteins during vascular development. We focus on existing in vivo and 
in vitro models and known human disease phenotypes and highlight potential mechanisms of DOCK protein dysfunction in 
the pathogenesis of vascular disease.
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Introduction
Vasculogenesis is the development of a primary blood sys-
tem during embryogenesis, via the de novo formation of 
blood vessels [1]. Vessels develop when endothelial pre-
cursor cells in the embryonic mesenchyme form an aggre-
gate, which mature into small, single-layered endothelial 
tubes [2]. The primary blood vessels formed in this process 
are stable and allow blood flow in the developing embryo. 
However, these vessels have poor functionality and require 
further re-modelling via angiogenesis. Sprouting angio-
genesis is guided by endothelial tip cells and promotes the 
expansion of existing vessels [2]. Tip cells are distinct from 
endothelial stalk cells by their position, dynamic filopodia 
and migratory behaviour, which defines the direction of 
new sprout growth [3]. The existing vessel wall is disas-
sembled by enzymatic degradation, for example by matrix 
metalloproteinases, of the extracellular matrix (ECM) archi-
tecture and basal lamina. Endothelial tip cells migrate into 
the perivascular layer towards an initial chemotactic factor, 
such as vascular endothelial growth factor (VEGF) or Notch 
signalling, followed by endothelial cell invasion of the ECM 
[2, 3]. Endothelial stalk cells proliferate to facilitate vessel 
sprouting, enabled by the loss of cell-to-cell contact, and 
the lumen capillary begins to form by stalk cell coalescence 
[2]. Once the vessel has fully expanded, endothelial cell 
proliferation and migration are inhibited by anti-angiogenic 
factors. The basal lamina reconstitutes, the vessel wall re-
assembles and the remodelled vessels then re-stabilise and 
mature by recruiting pericytes or vascular smooth muscle 
cells (VSMCs) [2]. Together, these cells encase the endothe-
lial tube, protecting the ECM and supporting the vessel [2]. 
As such, the migration and proliferation of endothelial cells 
and VSMCs are critical processes in the development of 
functional vascular networks and are known to be influenced 
by the activity of small Rho GTPases (Fig. 1).
The dedicator of cytokinesis (DOCK) protein family has 
been implicated in critical cellular processes such as cell 
migration and adhesion, due to its role in the regulation of 
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small Rho GTPases. Until recently, the DOCK family has 
been principally studied in relation to neuronal development, 
identifying a major role for DOCK proteins in neuronal cell 
functions and neurological disease [4–10]. Advances in our 
understanding of DOCK protein function in brain develop-
ment and neurological disease has been previously pub-
lished [11] so will not be further reviewed here. However, 
research over the last decade has determined that multiple 
DOCK proteins also function within the vascular system 
both experimentally and, critically, in the context of human 
disease. Taken together, 64 % (7/11) of DOCK proteins have 
now been demonstrated to regulate vascular processes, sug-
gesting that further investigation of this protein family in 
pertinent vascular cell types is both important and timely. 
This review collates the existing evidence supporting a role 
for the DOCK family proteins in vascular development and 
cardiovascular disease, providing a specific perspective to 
establish a framework for directed research in this important 
field.
Small Rho GTPases
Rho GTPases function as molecular switches, cycling 
between their active guanosine-5′-triphosphate (GTP)-
bound and inactive guanosine diphosphate (GDP)-bound 
states. The best characterised of these are RHOA, ras-
related C3 botulinum toxin substrate 1 (RAC1) and cell 
division cycle 42 (CDC42) [12]. Rho GTPase activity is 
controlled by the opposing actions of guanine nucleotide 
exchange factors (GEFs), GTPase-activating proteins 
(GAPs) and guanine nucleotide dissociation inhibitors 
(GDIs). GEF regulators activate GTPases by promoting 
the exchange of GDP for GTP. The Rho GEF family com-
prises approximately 80 members, divided into typical 
(Dbl) and atypical (DOCK) categories, and has been most 
commonly implicated in the development of neurological 
disorders and cancers [11, 13, 14]. Conversely, the GAP 
family, consisting of around 60 members, catalyse the 





























Fig. 1  DOCK protein activation of small Rho GTPases in endothelial 
tip cells. Schematic of the effector pathways downstream of RAC1 
and CDC42, following GEF-mediated activation by DOCK proteins. 
The specific DOCK subfamily binding partners are detailed in Fig. 3. 
Activation of RAC1 and CDC42 regulates lamellipodia or filopo-
dia formation, respectively, via actin polymerisation and cytoskel-
eton organisation. CDC42 is also involved in podosome assembly, 
however the regulation of this process by DOCK proteins remains 
unknown. Arp2/3 actin-related protein complex 2/3, GDP guanosine-
5′-diphosphate, GTP guanosine-5′-triphosphate, GEF guanine nucleo-
tide exchange factor, LIMK LIM kinase, PAK serine/threonine-protein 
kinase; VASP vasodilator-stimulated phosphoprotein, WASP Wiskott–
Aldrich syndrome protein, WAVE  regulatory complex
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to their inactivation [15, 16]. In a similar fashion, GDIs 
bind to and stabilise GDP-bound small GTPases, seques-
tering them in the cytoplasm and therefore preventing the 
spontaneous GEF-catalysed guanine nucleotide exchange 
reaction [15].
GEF-mediated activation of Rho GTPases contrib-
utes to dynamic actin cytoskeletal assembly and rear-
rangement, forming the basis of cell-to-cell adhesion and 
migration [17, 18]. CDC42 is a small Rho GTPase pre-
sent in most eukaryotes and is known for its role in the 
regulation of actin-based morphogenesis and cell polar-
ity [19]. By directing filopodia formation, CDC42 modu-
lates cell adhesion, migration and invasion in many cell 
types, including neurons, endothelial cells and VSMCs 
[17, 18]. CDC42-driven filopodia formation at the lead-
ing edge of endothelial tip cells has been shown to be 
required for angiogenesis and vessel patterning through 
the development of membrane protrusions, micropinocy-
tosis, endothelial cell barriers, adherens junctions and tube 
formation [17–21]. In vascular development, filopodia 
emerge from endothelial tip cells in response to CDC42 
activation, to regulate cell shape and migration, vascular 
branching and sensing of the microenvironment [22]. Filo-
podia are produced by the polymerisation of unbranched 
actin filaments, which are then arranged in parallel bundles 
at the filopodium tip [23]. This CDC42-induced localised 
actin polymerisation at the cell membrane promotes fila-
ment elongation via numerous pathways; CDC42 directly 
activates formin family proteins to nucleate and advance 
actin filament extension, whereas activation of Wiskott-
Aldrich syndrome proteins (WASPs) up-regulates the 
actin-related protein 2/3 (ARP2/3) complex to produce 
branched actin filament networks [24]. Actin elongation 
is stimulated by the activation of uncapping proteins, for 
example, vasodilator-stimulated phosphoprotein (VASP), 
delivered to the growing filopodium tip by molecules such 
as myosin X [21]. CDC42 may also activate the IRSp53 
adapter protein, which links actin to the membrane and 
promotes clustering of the uncapping protein (Fig. 1) [25, 
26]. Filopodia formation is a dynamic process owing to 
the continuous assembly and disassembly of the actin fila-
ments. Actin disassembly at the filopodium tip is typically 
cofilin- or gelsolin-mediated, but may also be driven by 
actin depolymerisation and retraction forces applied to the 
filopodium actin filaments by non-muscle myosin II. Inter-
estingly, several molecules are common to both neural and 
vascular development, for example, neuropilin-1 (NRP1) 
is required for tip cell guidance in the developing central 
nervous system (CNS) as well as for CDC42-mediated 
filopodia formation in endothelial tips cells [27, 28]. To 
facilitate cell migration, filopodial protrusions must be 
stabilised by adherence of the filopodia to the ECM via 
focal adhesions (FAs). In both neuronal growth cones and 
endothelial tip cells, this mechanism physically links the 
actin cytoskeleton to the ECM via integrins to mediate 
cell advance.
In a similar fashion, RAC1 mediates lamellipodia forma-
tion, which is required for blood vessel development and 
has been shown to promote migration, adhesion, angiogenic 
sprouting and the permeability responses of endothelial cells 
to VEGF both in vivo and in vitro [17, 18, 29, 30]. Like 
CDC42, RAC1-mediated lamellipodia formation may be 
driven by the activation of the WASP-related WAVE regula-
tory complex, which promotes actin filament nucleation [31]. 
The ARP2/3 complex is stimulated to advance branched 
actin nucleation, whilst filament length is controlled by 
elongation factors, such as VASP and formin family mem-
bers [31]. The serine/threonine-protein kinase (PAK) family 
contributes towards actin polymerisation in both filopodia 
and lamellipodia formation, and becomes active only when 
bound to either RAC1 or CDC42 [32]. PAKs have many 
downstream effectors, including LIM kinase (LIMK), to 
promote actin polymerisation and bundling [32]. As with 
filopodia, lamellipodial actin depolymerisation is propelled 
by severing proteins, such as cofilin (Fig. 1).
Further support for CDC42 involvement in mammalian 
vascular development is demonstrated by its conserved func-
tion in zebrafish, where Cdc42 is activated by pro-angio-
genic Arfgef9b and has been found to regulate filopodia and 
endothelial cell guidance mechanisms during angiogenesis 
[33]. In mice, compromised blood vessel formation during 
development is seen in Cdc42 knockout and endothelial-
specific deletion models [18]. Moreover, in the mouse retinal 
vasculature, CDC42 activation has been associated with the 
pro-angiogenic factor NRP1, demonstrating inhibition of 
cellular protrusion upon Nrp1 and Cdc42 knockdown, a find-
ing that has been replicated in zebrafish models [28]. Both 
CDC42 and RAC1 have also been shown to be essential for 
vascular development in vitro. Whilst CDC42 is required 
for protrusion formation and angiogenic sprouting, RAC1 
knockout endothelial cells are unable to contribute towards 
important angiogenic processes, such as tip cell migra-
tion, owing to their inability to form lamellipodia and FAs 
[29]. This is exemplified by Rac1-deficient mice, which are 
embryonic lethal by embryonic day 9.5 (E9.5), most likely 
due to defective development of major blood vessels and 
lack of small vessels observed in the embryo [29]. There-
fore, through their respective functions in controlling actin 
cytoskeleton reorganisation, both CDC42 and RAC1 dem-
onstrate roles in key cellular processes required for vascu-
logenesis and angiogenesis.
The DOCK protein family
The DOCK proteins are a family of Rho GEFs known to 
regulate the small Rho GTPases CDC42 and RAC1. The 
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family is subdivided into four groups, depending on their 
GTPase specificity and functional domains (Fig. 2). The 
DOCK-A (DOCK1, -2, and -5) and DOCK-B (DOCK3 and 
-4) subfamilies are generally specific for RAC1 activation 
and share the highest protein structure similarity of all 
DOCK subfamilies, including an N-terminal Src homology 
3 (SH3) domain, two DOCK homology regions (DHR-1 
and DHR-2), an armadillo repeat motif and a C-terminal 
proline-rich domain [34–38]. In addition, DOCK-A pro-
teins, but not DOCK-B, contain a helical domain towards 
their N-terminus. The DOCK-C subgroup (DOCK6, -7 and 
-8) regulate the activity of both RAC1 and CDC42 [39, 
40]. The only recognisable functional domains of this sub-
set are the DHR-1 and -2 domains and armadillo repeat. 
Finally, the DOCK-D subfamily (DOCK9, -10 and -11) all 
contain an N-terminal pleckstrin homology (PH) domain, 
which binds phosphoinositides to facilitate DOCK-D pro-
tein translocation to the membrane. The DOCK-D pro-
teins generally display CDC42 specificity, although both 
DOCK9 and -10 have also been implicated in RAC1 acti-
vation [35, 38, 41–43].
Unlike other Rho GEFs, DOCK proteins are not reliant 
upon PH and Dbl homology (DH) domains for GEF activity 
and membrane localisation [36, 39]. Rather, DOCK proteins 
are structurally related by their conserved functional DHR-1 
and DHR-2 domains. DHR-1 mediates the localisation of 
the protein to the membrane via lipid, namely phosphati-
dylinositol (3,4,5)-trisphosphate  (PIP3), interaction.  PIP3 is 
a product of phosphatidylinositol 3-kinase (PI3K) activation, 
a key pathway in the regulation of proliferation, migration 
and adhesion, with a well-documented role in angiogenic 
processes through its phosphorylation of protein kinase B 
(AKT) [44]. At the plasma membrane, the DHR-2 domain 
binds the target small Rho GTPase to catalyse GTP-GDP 
exchange, leading to its activation and thus initiating the 
cascade of Rho GTPase effector proteins resulting in actin 
polymerisation and, in turn, lamellipodia and filopodia for-
mation (Fig. 1) [36, 37]. The DHR-2 region comprises three 
Fig. 2  Structures of the DOCK 
protein subfamilies a–d. The 
DOCK protein family com-
prises 11 proteins, grouped into 
four subfamilies. Members of 
each subfamily share similar 
protein structure and functional 
domains. ARM armadillo repeat, 
DHR DOCK homology region, 
DOCK dedicator of cytokinesis, 
HD helix domain, PxxP proline-
rich region, PH pleckstrin 




lobes, known as A, B and C [45]. Through extensive contact 
with lobe B, lobe A stabilises the domain, whereas lobes B 
and C contain the GTPase binding site and catalytic centre 
to mediate guanine exchange of the target small Rho GTPase 
[37, 46]. Lobe B is comprised of two anti-parallel sheets and 
lobes A and C are near-identical anti-parallel alpha heli-
cal bundles, each consisting of four alpha-helices [45]. The 
SH3 domain, shared by the DOCK-A and -B subfamilies, 
binds to the PH domain of engulfment and cell motility 
(ELMO) proteins, required for activation of DOCK GEF 
activity [47–50]. The DOCK-A and -B C-terminal proline-
rich region has been found to bind phosphatidic acid (PA) 
as well as SH3-containing adaptor proteins, such as CRK, 
which contribute towards the functional complex required 
for DOCK-mediated Rho GTPase activity [48, 51].
To date, DOCK3, -8, -10 and -11 have not been asso-
ciated with vascular development and remain primarily 
implicated in the pathogenesis of neurological disease and/
or immune-related disorders (Table 1). By contrast, mount-
ing evidence supports an argument for the importance of the 
other DOCK family members in critical vascular processes, 
potentially implicating the wider DOCK protein family in 
the development of vascular disease.
DOCK1
  DOCK1, formerly named DOCK180 due to its 180 kDa 
protein mass, was the first of the DOCK family proteins to be 
characterised [52]. Mammalian DOCK1 protein expression 
is distributed throughout all tissues, and enriched DOCK1 
expression has been identified in pulmonary artery endothe-
lial cells, human umbilical vein endothelial cells (HUVECs) 
and human microvascular endothelial cells (HMVECs) [16, 
53, 54]. Despite exhibiting relatively low tissue specificity, 
DOCK1 plays a specific role in the formation of skeletal 
muscle, as demonstrated in zebrafish, fruit fly and mouse 
models [55, 56]. This activity is regulated on a cellular 
level by the formation of several regulatory complexes 
between DOCK1 and different binding partners (Fig. 3a). 
Of particular interest, DOCK1, as well as DOCK2, -4 and 
-5, interacts with ELMO1 or -2, whereby the binding of 
ELMO1/2 induces a conformational change in DOCK1, 
releasing an auto-inhibitory mechanism and enabling 
DOCK1 to act as a RAC1-specific GEF [35, 36, 55]. Once 
associated with DOCK1, ELMO1 can interact with RHOG, 
promoting translocation of DOCK1 to the plasma mem-
brane, where the DOCK1/ELMO1/RHOG complex activates 
RAC1 [9, 57]. Alternatively, DOCK1 translocation from the 
cytosol to the cell membrane can be mediated by interactions 
between the DOCK1 DHR-1 domain and membranous  PIP3 
[36, 58]. Upon membrane localisation, DOCK1 activates 
RAC1 to facilitate RAC1-dependent actin reorganisation at 
the leading edge of the cell, which is required for directional 
cell movement [36, 59].
  Conversely, ELMO2 has been found to recruit and 
complex with DOCK1 at initial cell-cell contacts in Madin-
Darby canine kidney cells [50]. The DOCK1/ELMO2 
complex is essential for rapid recruitment and spreading of 
E-cadherin, actin reorganisation, localised RAC1 activity 
and strong cell-cell adhesion. In a vascular context, loss-of-
function mutations in ELMO2 can cause autosomal reces-
sive intraosseous vascular malformation (VMOS), which 
results in malformed blood vessels lacking a mature vas-
cular smooth muscle layer [60]. Analysis of VMOS fibro-
blasts identified a correlation of ELMO2 deficiency with the 
down-regulation of DOCK1, resulting in impaired RAC1-
dependent cell migration [60].
Further involvement of DOCK1 in cell migration may be 
partially regulated in a VEGF-independent manner, as tel-
omerase-immortalised HMVECs showed increased motility 
following polypyrimidine tract binding protein 1 (PTPB1) 
inhibition, through activation of the DOCK1/RAC1 pathway 
[61]. PTPB1 is known to impede VEGF receptor (VEGFR) 
signalling in endothelial cells, resulting in decreased cell 
motility [62]. Upon integrin stimulation at the membrane, 
FAK, epidermal growth factor receptor (EGFR) and platelet-
derived growth factor receptor (PDGFR) induce DOCK1 
phosphorylation by Src family kinases, promoting the 
association of DOCK1 with the P130CAS (BCAR1) and 
CRK scaffold proteins (Fig. 3a) [54]. Interestingly, FAK, 
P130CAS and DOCK1 have all been implicated in axonal 
outgrowth, driven by DCC receptor interaction in netrin-1 
(NTN1) signalling, an established angiogenic pathway [5, 
63]. Under PTPB1 inhibition, DOCK1-P130CAS-CRK 
complex formation is promoted, leading to increased RAC1 
activity. Alternatively, the DOCK1-P130CAS-CRK com-
plex can be recruited to FAs by further association with 
FA-essential paxillin, wherein RAC1 activation specifically 
drives increased migration of human glioma cells [54]. In 
human microvascular cells, this paxillin-CRK-DOCK1 
complex was found to be disassembled by TIMP metallo-
peptidase inhibitor 2 (TIMP2) in favour of paxillin-CRK-
C3G complex formation, switching GTPase activation from 
RAC1 to RAP1 [64]. As TIMP2 is a suppressor of migra-
tion and impedes DOCK1-mediated cell motility, these data 
imply a potentially global role for DOCK1 in cell migration, 
further substantiated by siRNA-mediated DOCK1 knock-
down studies in HUVECs and intestinal epithelial cells [65]. 
In this study, DOCK1 depletion reduced cell spreading, cell 
migration and lamellipodial extensions at the migratory edge 
of the cell, indicating that reduced RAC1 activation caused 
by DOCK1 knockdown is the primary cause for these pheno-
types. These findings were mimicked by DOCK5 depletion 
in the same study [65]. The high amino acid conservation 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































towards a common  PIP3-associated mechanism for mediat-
ing cell migration in DOCK-expressing cell types. Interest-
ingly, the DOCK1/ELMO1 complex has also been found 
to associate with the Dbl-RhoGEFs Intersectin-1 and -2 
(ITSN1/2), known to contribute to intercellular endothelial 
adhesions [66]. DOCK1 is the only DOCK protein known so 
far to interact with typical RhoGEFs and, when complexed, 
DOCK1/ELMO1-ITSN1/2 directly interacts with G-protein 
coupled receptor 124 (GPR124) to aid cell adhesion [66]. 
As GPR124 is associated with brain angiogenesis and 
blood-brain-barrier integrity, and has been shown to regu-
late CDC42-mediated filopodia formation in human brain 
vascular pericytes [67], these observations provide further 
evidence to implicate both typical and atypical Rho GTPase 




























































































Fig. 3  DOCK protein family-specific signalling pathways regulating 
CDC42 and RAC1 activity. a Overview of the receptors, signalling 
pathways and binding complexes regulating the DOCK-A and -B 
subfamilies. Activation of DOCK proteins 1–5 results in the guanine 
nucleotide exchange of the small Rho GTPase RAC1, leading to its 
activation. b Known regulatory pathways of proteins in subfamilies 
DOCK-C and -D. Stimulation of DOCK proteins 6–11 initiates acti-
vation of RAC1, CDC42, or both. BDNF brain-derived neurotrophic 
factor, CXCL12  C-X-C motif chemokine 12, CXCR4  C-X-C motif 
chemokine receptor type 4, DOCK  dedicator of cytokinesis protein, 
ELMO1  engulfment and cell motility protein 1, EGF  epidermal 
growth factor, EGFR  epidermal growth factor receptor, FAK  focal 
adhesion kinase, GDP  guanosine diphosphate, GTP  guanosine 
triphosphate, NRG1 neuregulin 1, P phosphate, PA phosphatidic acid, 
PDGF-BB platelet-derived growth factor subunit B, PDGFR platelet-
derived growth factor receptor, PI3K  phosphatidylinositol 3-kinase, 
PIP2 phosphatidylinositol (4, 5)-biphosphate, PIP3 phosphatidylino-
sitol (3, 4, 5)-triphosphate, PP2A protein phosphatase 2, STAT3 sig-
nal transducer and activator of transcription 3, TACC3  transforming 
acidic coiled-coil-containing protein 3, TGFB  transforming growth 
factor-beta, TrkB  tropomyosin receptor kinase B, WASP  Wiskott–
Aldrich syndrome protein, WAVE regulatory complex
Angiogenesis 
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A relationship between DOCK1 and the cardiovascular 
system in vivo was first observed in 2010, when Dock1-
deficient mice were observed to have developed large 
edema at E14.5 [51]. Upon dissection of Dock1-deficient 
embryos, defects in cardiovascular development were identi-
fied, namely sub-membranous ventricular septal defect and 
double outlet right ventricle [51]. These cardiac abnormali-
ties were noted to resemble the phenotype observed with 
knockdown of chemokine receptor type 4 (Cxcr4), a gene 
encoding the receptor for CXCL12 and known to be criti-
cal for vascular development and endothelial cell morphol-
ogy and branching [68–70]. Co-expression of DOCK1 and 
CXCR4 in cardiac and vascular endothelial cell lineages 
suggested a possible role for DOCK1 in endothelial cellular 
processes, such as cell invasion of the ECM, although it is 
currently unclear whether DOCK proteins are activated dur-
ing endothelial ECM cell invasion [51]. Of interest, CDC42 
is a key player in the formation of invasive podosomes, 
through interaction with its downstream effectors WASP 
and ARP2/3. However, the role of DOCK proteins in this 
process remains to be delineated (Fig. 1) [71]. Subsequently, 
investigation of DOCK1 function in vascular endothelial 
cells using chemotaxis assays identified a role for DOCK1 
downstream of CXCR4 in cardiac endothelial cell migra-
tion and membrane ruffling in response to CXCL12. As 
CXCL12-induced activation of CXCR4 leads to associa-
tion with ELMO1 to promote recruitment and activation of 
DOCK1 to the plasma membrane [72], these findings point 
towards a mechanism of action whereby CXCR4 stimulates 
DOCK1-mediated RAC1 activation to control endothelial 
cell migration and invasion via actin cytoskeleton reorgani-
sation during cardiovascular development [51].
Consistent with the vascular phenotype in Dock1−/− mice, 
morpholino-directed dock1 knockdown in zebrafish induced 
notable vascular defects, but only at higher oligo concen-
trations [55]. It is unclear whether this observation was a 
secondary effect derived from the known Dock1 function in 
myoblast fusion, leading to trunk defects upon dock1 knock-
down [55]. Nonetheless, the shift in zebrafish dock1 expres-
sion from a ubiquitous pattern during early somitogenesis, 
to a more specific vascular expression in the dorsal aorta and 
posterior cardinal vein later in development, would support 
a potential role during vascular development [55]. This tem-
poral and spatial expression pattern is mimicked by elmo1, 
which demonstrates non-specific expression throughout the 
embryo during early somitogenesis and adopts a vascula-
ture- and CNS-specific pattern by 24 hours post fertilisa-
tion [55]. Investigation of elmo1 activity in early zebrafish 
development confirmed its important role in the developing 
vasculature, with morpholino knockdown inducing mul-
tiple vascular-related phenotypes, including heart edema, 
accumulation of blood in the yolk sac, deformation of the 
intersomitic vessels and agenesis of the dorsal longitudinal 
anastomotic vessel [55]. Of note, this study identified Ntn1 
as an upstream activator of the Elmo1/Dock1/Rac1 sig-
nalling cascade in zebrafish, confirming the Ntn1/Dock1 
interaction in a vascular context as well as in axonal out-
growth, as discussed above [5, 55]. Additional zebrafish 
studies have demonstrated the effects of Dock1 and Elmo1 
overexpression in reducing endothelial cell apoptosis and 
inducing angiogenesis, further supported by HUVEC stud-
ies confirming the same results under DOCK1 and ELMO1 
overexpression and identifying activation of the pro-survival 
PI3K/AKT signalling cascade by DOCK1 and ELMO1 [63]. 
As DOCK1-mediated GEF activity is contingent on forma-
tion of an ELMO1/DOCK1 complex in both zebrafish and 
mammalian systems, these observations indicate an essential 
mechanism of ELMO1/DOCK1-mediated RAC1 activation 
during vascular development.
Although not yet implicated in human vascular disease, 
these combined data imply a conserved role for DOCK1 in 
the control of mammalian cardiac development and vascu-
larisation, under the regulation of multiple, vascular cell-
specific genes.
DOCK2
In stark contrast to DOCK1, which is expressed through-
out all tissue types aside from peripheral blood leukocytes, 
DOCK2 expression is confined predominantly to haemat-
opoietic cells, but is confirmed to also have low-level expres-
sion in HMVECs [53, 59]. DOCK2 shares 63.2% identity 
with DOCK1, excluding the carboxyl terminal variable 
regions [45]. Unlike DOCK1, induction of DOCK2 expres-
sion in normal rat kidney cells led to a rounding and detach-
ment phenotype in vitro, thought to be caused by RAC1 
activation [59]. Despite both proteins driving RAC1 activa-
tion, it is thought that the different morphological effects 
observed with DOCK1 and DOCK2 over-expression may 
stem from alternative intracellular localisation of these pro-
teins [59]. However, this is yet to be fully elucidated, and 
different, cell-specific mechanisms of DOCK1 and -2 activa-
tion may also contribute to the disparate cellular responses.
Known for its involvement in immune regulation, DOCK2 
regulates lymphocyte activation and migration [34, 73]. This 
has been demonstrated in a Dock2−/− mouse model, where 
T and B lymphocyte migration was inhibited, and RAC1 
activation and actin polymerisation were virtually abolished 
[34]. Similar to DOCK1, DOCK2 is regulated by ELMO1 
which drives binding of DOCK2 to  PIP3.  PIP3 association 
translocates DOCK2 to the membrane in a PI3K-dependent 
manner, leading to RAC1 activation which in turn serves as 
a positive feedback loop, stabilising  PIP3 at the cell’s lead-
ing edge.
Interestingly, DOCK2 has also been implicated in vascu-
lar remodelling [74], wherein VSMCs de-differentiate from 
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a contractile to a synthetic phenotype, triggered by damage 
to the blood vessel walls and followed by VSMC migration 
and proliferation. This can lead to the narrowing of the blood 
vessel lumen. Low endogenous DOCK2 expression is main-
tained in VSMCs, but is drastically increased by the addition 
of platelet-derived growth factor subunit B (PDGF-BB), a 
molecule known to stimulate VSMC phenotypic modulation 
[74]. Stimulation of DOCK2 expression correlates with a 
decrease in the expression of VSMC marker proteins, such 
as serum response factor (SRF) and Mycod. Conversely, 
DOCK2 knockout was shown to increase VSMC marker 
protein expression, supporting an argument for the require-
ment of low level DOCK2 expression in VSMCs to main-
tain contractile protein homeostasis [74]. A further study 
has implicated a role for DOCK2 in neointima formation, 
which is the generation of scar tissue in the blood vessel 
lumen after vein graft [75]. This was identified when unusu-
ally high levels of DOCK2 expression were detected in vein 
grafts of male Sprague-Dawley rats that underwent jugular 
vein-carotid artery bypass grafting [75]. Adding to existing 
knowledge of the role of DOCK2 in VSMC differentiation, 
DOCK2 knockdown was noted to inhibit rat VSMC migra-
tion and proliferation, whereas over-expression significantly 
increased these processes [75]. As VSMC migration and 
proliferation are key processes in angiogenesis, these find-
ings point towards a role for DOCK2 in the maintenance of 
healthy mammalian blood vessels. To further validate the 
involvement of DOCK2 in vessel maintenance, the knock-
down of endogenous DOCK2 in grafted veins was shown to 
reduce neointimal formation and lead to improved hemody-
namics in vein grafts [75]. Despite this clear association with 
vessel maintenance, DOCK2 has not yet been implicated in 
human vascular disease, but has been reported to cause an 
inherited immunodeficiency disorder [76].
DOCK4, ‑5 and ‑7
DOCK4 demonstrates diverse tissue expression, includ-
ing in HUVECs and HMVECs, and has been observed to 
regulate the activity of both RAC1 and, in contrast to other 
DOCK family members, RAP1 [16, 53, 77]. RAC1 activa-
tion requires the DHR-2 domain and DOCK4 binding to the 
PH domain-containing protein ELMO1/2, similar to other 
DOCK-A and -B subfamily members [78]. However, the 
DOCK4 SH3 domain has a unique role in negatively regulat-
ing RAC1 activity [78]. The DOCK4 functional domains are 
also important in protein expression localisation, as exempli-
fied in a splice isoform of DOCK4 lacking exon 49, which 
contains a conserved region [77]. Tissue expression of the 
alternatively spliced isoform was restricted to the stereocilia 
of the cochlea and retina, as opposed to the usual widespread 
expression of full-length DOCK4 in a diverse range of tis-
sues [77].
Analogous to other DOCK family proteins, DOCK4 is 
known to contribute towards cell migration [8, 78–80]. This 
has been demonstrated in fibroblast cells, where DOCK4 
activated RAC1 at the cell membrane [78]. In this study, 
over-expression of wild-type DOCK4 was found to signifi-
cantly increase cell migration, by comparison to constructs 
containing either a C-terminal or DHR-2 domain mutation.
Several reports have implicated DOCK4 involvement in 
vascular-type cells, noted initially when the microRNA mir-
21 exhibited downstream effects on DOCK4, DOCK5 and 
DOCK7 expression in VSMCs [79]. mir-21 is known to play 
a critical function in the development of cardiac hypertrophy 
and fibrosis, and influences cell proliferation and migration 
through targeting the knockdown of downstream effectors 
[68]. Speculation for the role of mir-21 in vascular develop-
ment is strengthened by its association with bone morpho-
genetic protein (BMP) and transforming growth factor-beta 
(TGF-β) signalling, known to promote a contractible phe-
notype in VSMCs by targeting the programmed cell death 
4 (PDCD4) gene [79]. Indeed, upon mir-21 over-expression 
in pulmonary artery smooth muscle cells, DOCK proteins 
4–7, 9 and 10 were found to be down-regulated, indicating 
a notable association between the DOCK family of proteins 
and this cell type [79]. Further investigation using siRNA 
identified a significant decrease of VSMC migration upon 
knockdown of DOCK4, -5 and -7, and a reduction of VSMC 
contraction upon DOCK4 and DOCK5 knockdown, but not 
DOCK7. This suggests a specific function for DOCK4 and 
-5 in the regulation of vascular cell contractility, substanti-
ated by the elevated expression of contractile genes upon 
siRNA targeting of DOCK4 and -5 [79]. As these proteins 
contain multiple SH3 domains which are not present in 
DOCK7, it is possible that cytoskeletal remodelling may 
be mediated through SH3 domain interactions with other 
signalling molecules.
DOCK4 involvement in vascular development was further 
consolidated in a more physiologically relevant study, using 
siRNA-based screens in an organotypic angiogenesis sys-
tem which recapitulates endothelial cell association, vessel 
sprouting and tubule establishment [80]. Here, the role of 
DOCK4 was investigated in 3D culture of endothelial cells 
seeded onto a confluent layer of fibroblasts. Knockdown 
with DOCK4-specific siRNA led to a marked decrease in the 
number of vessel branches that developed, suggesting that 
DOCK4 promotes vessel sprouting. The remaining develop-
ing tubules were thinner and with fewer lateral cell-to-cell 
contacts, implicating DOCK4 in tubule development and 
endothelial cell adhesion, a critical process in angiogenesis 
[80]. To further underline the importance of DOCK4 in 
cell adhesion, siRNA-mediated Dock4 depletion in normal 
mouse osteoblasts elicited a marked suppression of adherens 
junctions [81]. When examined in vivo, homozygous Dock4 
knockout in the mouse caused early embryonic lethality, 
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however heterozygous Dock4+/− mice exhibited a variety of 
angiogenic-associated defects, including a decrease in the 
blood vessel lumen size, seen in the brain parenchyma of 
E13.5 embryos [80]. This decrease in lumen size was not 
associated with pericyte coverage of the vessel, suggesting 
that another mechanism may be affected, for example cell 
contractility or motility [79, 80]. Combined, these results 
provide evidence indicating a role for DOCK4 in endothelial 
cell protrusive activity, tubule remodelling, organisation of 
lateral contacts and lumen formation.
In the context of vascular disease, DOCK4 was recently 
implicated in a mechanism for atherogenesis, the formation 
of arterial fatty deposits, and in neovascularisation following 
an ischaemic event [82, 83]. Specifically, DOCK4 was noted 
as a critical interacting partner of scavenger receptor class 
B type 1 (SR-B1), a receptor observed in mice to bind LDL 
and mediate its delivery into the arteries, instigating the cas-
cade towards the development of atherosclerosis [82]. Co-
expression of SR-B1 and DOCK4 in vivo was observed in 
the aortic endothelium of mouse models, and increased lev-
els of both proteins detected in the aorta prior to atheroscle-
rotic lesion formation [82]. DOCK4 knockdown decreased 
the internalisation of SR-B1 in endothelial cells, impeding 
the delivery of circulating LDL into the sub-endothelial 
space by SR-B1 and therefore reducing atherosclerotic lesion 
formation [82].
Additional support for the potential role of DOCK5 in 
vascular development lies in the shared regulatory mecha-
nisms acting on both DOCK1 and DOCK5. Like DOCK1, 
DOCK5 localises to FAs via a DOCK5-P130CAS-CRK 
complex, implying a similar role for DOCK5 in cell adhe-
sion. Of interest, Dock5 knockout mice display increased 
trabecular bone mass due to defective osteoclasts impeding 
microtubule-dependent podosome assembly [84]. However, 
DOCK5 interactions with ARF GTPase-activating protein 2 
(GIT2) result in reduced GEF activities, in contrast to the 
positive regulation of DOCK1 by GIT1 and -2 for recruit-
ment to FAs [85]. Although compelling, both DOCK5 and 
DOCK7 have yet to be thoroughly investigated in a vascular 
context, hence additional work is required to fully elucidate 
their respective regulatory mechanisms.
DOCK6
DOCK6, alternatively named ZIR1, has been strongly 
associated with a role in neuronal cell migration [7, 39]. 
Nonetheless, Dock6 demonstrates localised expression to 
the developing heart and growing limb buds in the E10.5- 
and E11.5-stage mouse embryo and is shown to be highly 
expressed in both HUVECs and HMVECs [16, 53, 86]. In 
a neuronal context, DOCK6 activity is known to be regu-
lated by its phosphorylation state; DOCK6 GEF activity is 
inhibited by AKT-mediated phosphorylation at Ser1194, 
whereas Ser1194 dephosphorylation by phosphatase PP2A 
interaction promotes DOCK6-mediated RAC1 and CDC42 
activation [7]. However, regulation of DOCK6-mediated 
GEF activity in a vascular context remains to be explored.
DOCK6 was identified as the second causal gene of 
Adams-Oliver syndrome (AOS), a rare developmental dis-
order characterised primarily by the congenital absence of 
skin on the scalp, known as aplasia cutis congenita (ACC), 
and terminal transverse limb defects (TTLD), both of 
which present with a wide range of severity. These primary 
features may be associated with a wide array of additional 
clinical features, including cardiovascular, neurological 
and ocular defects. Importantly, congenital heart defects 
and cutis marmorata telangiectatica congenita (CMTC), 
a rare cutaneous vascular anomaly, are each observed in 
~ 20 % of AOS cases [87]. DOCK6 mutations underlie an 
autosomal recessive form of AOS and the vast majority 
are predicted to lead to a disruption of DOCK6 function, 
due to either premature protein truncation or degradation 
of mutant transcripts by nonsense-mediated mRNA decay. 
Consistent with a loss of GEF activity, patient-derived 
fibroblasts revealed actin cytoskeletal defects resembling 
CDC42 and/or RAC1 inactivation [86]. To date, ~ 20 inde-
pendent DOCK6 mutations have been described, account-
ing for 7 % of all reported AOS cases [88]. Predicted loss-
of-function variants cover all mutation types including 
missense and nonsense, and are located across the length 
of the gene [10, 86, 89–91].
Patients with DOCK6 mutations display a broad range 
of clinical presentations in addition to ACC and TTLD. Of 
significance, a large proportion of patients exhibit anoma-
lies associated with the heart and/or vasculature, implicat-
ing AOS-related DOCK6 dysregulation in aberrant vascu-
lar development [88]. Loss-of-function DOCK6 mutations 
are also strongly associated with CNS and structural eye 
abnormalities [10]. Furthermore, developmental delay and 
seizures have been identified in > 45 % of patients with 
microcephaly and, even in the absence of microcephaly, 
demonstrate strong correlation with the presence of impaired 
intracranial vascularisation [88]. Notably, abnormal pericyte 
recruitment, perhaps due to impaired pericyte migration, has 
been identified in post-mortem examination of AOS patients 
[92]. Ectasia and tortuosity of large veins, irregular medial 
thickness due to uneven mural cell deposition, and abnormal 
retinal vascularisation have all been observed [92]. Whilst 
the molecular causes of AOS in these patients remains 
unresolved, these characteristics may explain the observed 
clinical features in DOCK6-related AOS and suggest a role 
for the causal gene in the recruitment and migration of peri-
cytes during angiogenesis [10, 86, 89, 90]. However, the 
functional impact of AOS-specific mutations in vascular cell 




Interestingly, DOCK6 has been implicated in the TGF-β 
signalling pathway, which is critical for many cellular pro-
cesses including vascular development and homeostasis 
[93]. Importantly, TGF-β and BMP have roles in promot-
ing VSMC differentiation and maintaining the contractile 
phenotype of VSMCs [94]. TGF-β signalling induces the 
haematopoietic cell-specific microRNA mir-142-3p, which 
has been shown to down-regulate DOCK6 expression and 
simultaneously decrease cell migration in VSMCs, provid-
ing preliminary evidence for a role for DOCK6 dysregu-
lation in disrupted vascularisation [93]. Transient DOCK6 
knockdown has been reported to exhibit a much more severe 
phenotype in HeLa cells by comparison to AOS patient-
derived cells harbouring biallelic DOCK6 mutations [86, 
95]. This phenomenon may be partly explained by overlap-
ping functions between DOCK family members, leading to 
genetic compensation upon prolonged gene loss and reduc-
ing the severity of the phenotype. While one study iden-
tified an increase in RHOA activity in DOCK6-negative 
patient-derived cells, potentially highlighting a compen-
sation response mechanism, alterations in DOCK family 
gene expression upon stable DOCK6 knockdown remain 
unexplored [95]. Therefore, further investigation into the 
functional effects of solely DOCK6 knockdown on VSMCs 
is required. Nonetheless, the existing findings support an 
important role for DOCK6-mediated Rho GTPase dysregu-
lation in the development of AOS-related cardiovascular and 
neurological defects.
DOCK9
Similar to DOCK6, the DOCK-D subfamily member 
DOCK9 (also known as ZIZIMIN1) has been demonstrated 
to act as a GEF to both RAC1 and CDC42 [42, 43, 96]. 
In addition to strong associations with the nervous sys-
tem, DOCK9 is implicated in vascular development and 
is expressed in HUVECs [16]. In human epithelial cells, 
DOCK9 has been documented to interact with SMAD2 and 
-3 in response to TGF-β1 stimulation, indicating a potential 
role as a downstream effector in the TGF-β-mediated regula-
tion of cell motility [97]. VEGF promotes DOCK9 associa-
tion with DOCK4 to influence cellular actin dynamics [80]. 
Through knockdown studies in 3D endothelial cell culture, 
DOCK9 has been shown to contribute towards the develop-
ment of lateral and, to a lesser extent, tip filopodia [80]. 
More specifically, DOCK9 depletion resulted in the forma-
tion of tubules with a more linear morphology than their 
wild-type counterparts. In an attempt to further delineate 
the role of DOCK9 in cell morphology, inducible expression 
of DOCK9 was assessed in HeLa cells [43]. This resulted 
in reduced cell elongation and stress fibres, while inducing 
the formation of filopodia and membrane ruffles [43]. Taken 
together, these data indicate a requirement for DOCK9 in the 
remodelling of lateral organisation and the actin cytoskel-
eton in various cell types, including endothelial cells, and in 
vessel lumen morphogenesis [42, 43, 80].
Discussion and conclusions
Existing research highlights migration and proliferation as 
key cellular processes influenced by the DOCK family of 
proteins, through its regulation of CDC42 and RAC1 activ-
ity. While most of these findings have been documented in 
a neuronal context, it is becoming increasingly clear that 
DOCK proteins play an essential part in the development 
and maintenance of the vasculature and other systems 
(Table 1). By comparison to the nervous system, our under-
standing of the pathways controlling DOCK protein activity 
within a vascular context remains limited. However, some 
mechanisms of action may be inferred from their roles in 
neurogenesis, owing to the parallelisms between neural and 
vascular development. Both neuritogenesis and angiogen-
esis are reliant upon single cell branching, and the produc-
tive advance of neural growth cones or vascular tip cells 
depends on integrin-mediated adhesions to the local ECM 
for guidance in sprout pathfinding. As discussed, angiogenic 
sprouting relies heavily on actin cytoskeleton reorganisa-
tion due to the actions of active CDC42 and RAC1 and 
their downstream effector proteins. In neuronal branching 
morphogenesis, CDC42 is activated in response to guid-
ance molecules such as NTN1 and NRP1, which have each 
been shown to be required for tip cell guidance by CDC42 
activation and filopodia formation both in the developing 
CNS and vasculature [5, 27, 28]. Hypothetically, given the 
substantive evidence associating the DOCK protein family 
with neurogenesis, the numerous commonalities between 
neuronal and vascular advances during development may 
be extrapolated to build a speculative bridge linking DOCK 
proteins enriched in human endothelial cells to a potential 
angiogenic role [16, 53].
A number of vessel-specific and pro-angiogenic inter-
actors, such as CXCR4, NTN1 and BMP4, among others, 
have been associated with DOCK-mediated GEF activity 
in vascular cell types [51, 68, 79]. Of interest, members 
of the DOCK family are known to interact with proteins 
implicated in Notch signalling, for example DOCK3-Pre-
senilin and DOCK7-TSC1/2 [98, 99]. Whilst the involve-
ment of Notch signalling during vascular development 
is well-known, these DOCK-Notch pathway interactions 
have not yet been fully investigated in a vascular context. 
The role of the CXCR4/CXCL12 signalling pathway in 
DOCK protein regulation is of particular interest, owing 
to one of several known mechanisms of activation through 
the Delta-like canonical Notch ligand DLL4, demon-
strating a potential cross-over between the DOCK and 
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pro-angiogenic Notch signalling pathways, and its paral-
lel involvement in the activation of certain Dbl-family Rho 
GEFs [68, 69, 100]. For example, the Dbl family mem-
ber  PIP3-dependent RAC exchanger 1 (PREX1) medi-
ates angiogenic responses downstream of CXCL12 activ-
ity promoted by VEGF [101]. In this study, endogenous 
expression of PREX1 in endothelial cells was required for 
RAC1 activation, cell migration and in vitro angiogenesis 
in response to CXCL12 stimulation [101]. Considering the 
overlapping functions of the DOCK and Dbl GEF families 
in regulating the small Rho GTPases, it is tempting to 
speculate that these proteins may interact with CXCR4 in 
a similar manner and further implicate the pro-angiogenic 
VEGF pathway in the regulation of DOCK proteins.
The links between DOCK proteins and molecules associ-
ated with vascular development strongly imply functional 
importance of this family during angiogenesis. This pos-
tulation would be further supported by evidence of anti-
angiogenic factors inhibiting DOCK protein activity. How-
ever, DOCK regulation by anti-angiogenic factors has not 
yet been thoroughly investigated. Despite the functions of 
DOCK proteins in actin cytoskeleton remodelling by regu-
lation of RAC1 and CDC42, and the growing evidence 
implicating DOCK proteins in pro-angiogenic processes, 
current research indicates a defined role for VEGF recep-
tors upstream of DOCK4 and -9 activity only [80]. Impor-
tantly, although various angiogenic factors have been noted 
to contribute towards DOCK protein activation, very little 
is known about how these molecules interact to facilitate 
DOCK GEF activity. Findings such as these suggest that 
DOCK protein modulation in the vasculature is currently 
under-researched and a stronger focus to elucidate the path-
ways influencing DOCK activity in vascular biology would 
be advantageous.
DOCK family members share a high degree of conserva-
tion, particularly across the DHR-1 and DHR-2 functional 
domains, and demonstrate overlapping tissue expression. Yet, 
pathogenic variation in DOCK family genes are associated 
with a diverse range of human disorders, including develop-
mental, neurological and vascular abnormalities (Table 1). 
This review highlights that seven DOCK proteins (1, 2, 4–7 
and 9) have key functions within the cardiovascular and/or 
neurological systems. The differences in clinical phenotypes 
may be due to temporal and spatial expression of numerous 
factors, including miRNAs, which restrict DOCK gene expres-
sion to either vascular- or neuronal-specific tissue [79, 93], 
or binding partners and DOCK protein regulators, leading to 
tissue-specific GEF activity [51, 55]. Conversely, alteration 
of conserved sites is known to change the expression pat-
tern of some DOCK proteins [77]. It is possible that the less 
well-conserved functional domains, such as the SH3 and PH 
domains, could affect the localisation and binding activity of 
individual DOCK proteins and therefore lead to the range of 
phenotypes exhibited upon protein loss. However, this is yet 
to be explored.
The possibility that compensatory mechanisms may 
dampen the severity of a phenotype generated by DOCK6 pro-
tein depletion is an important consideration in the context of 
both the DOCK and Rho GTPase families, each of which have 
likely redundancy [55, 95]. The DOCK family contains 11 pro-
teins that specifically regulate RAC1, CDC42 or both, leaving 
much scope for genetic compensation upon the pathological 
down-regulation of one member. Thus, vascular effects caused 
by loss of DOCK protein function may have been masked in 
genetic models due to pathway redundancy disguising the phe-
notype. In this case, it would be interesting to quantify the gene 
expression and activity of other RAC1/CDC42-specific GAPs 
and GEFs in vascular tissue upon DOCK protein dysregula-
tion, to provide novel insight to additional DOCK proteins 
functioning within a vascular context.
Phenotypic assessment of DOCK-depleted mouse mod-
els has been largely targeted towards evaluating the impact 
on the nervous system (Table 1), therefore a comprehensive 
examination of the effect of DOCK protein loss on vascular 
development may be appropriate. As our understanding of the 
respective roles for DOCK proteins in vascular development 
and disease remains in its infancy, further investigation into the 
influence of this protein family and their regulation in vascu-
lar cell types is now warranted. Similar to DOCK proteins in 
non-vascular environments, it seems likely that several DOCK 
proteins will contribute to the migration and proliferation of 
critical cell types in angio- and vasculogenesis. Elucidation of 
the possible mechanisms of action in cytoskeleton reorganisa-
tion therefore has significant potential to provide valuable new 
insights into the roles of the remaining DOCK proteins and 
wider signalling pathways in development and maintenance 
of the vascular network.
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